Moreover, the Spanish Society of Medical Oncology clinical guidelines [37] for ovarian cancer indicate that PARPis induce cell death in HRRD-positive tumor cells through a “synthetic lethality” mechanism, with BRCA1 and BRCA2 mutations being one of the established causes of HRRD in tumors. The gene discussed is BRCA2; the disease is ovarian carcinoma.